When BHP Billiton Ltd.’s new chief executive officer Andrew Mackenzie got his doctorate in chemistry in 1980, the ground-breaking research attracted the attention of oil producers including Chevron Corp.
The use of tuberculosis drug isoniazid in conjunction with antiretroviral therapy to prevent the disease among HIV-infected patients is safe and cuts the incidence of TB by 37 percent, according to a study.
Inside a nondescript office building in central London, a roomful of men and women sit at computer screens and talk over Skype with people in faraway places. Sharp-edged Cantonese fills the air, and a flat-screen TV emits a continuous din. It’s the chanting, singing Midlands crowd at Birmingham, England’s Villa Park Stadium: Liverpool at Aston Villa. The match has just kicked off.
Prevention of tuberculosis, the world’s second-deadliest infectious disease, may unintentionally boost drug resistance of more dangerous strains of the bacteria, especially among HIV-infected patients, according to a study.